On January 1, 2013, AbbVie(1) became an independent company as a result of
the distribution by Abbott Laboratories (Abbott) of 100 percent of the
outstanding common stock of AbbVie to Abbott's shareholders. Each Abbott
shareholder of record as of the close of business on December 12, 2012 (the
Record Date) received one share of AbbVie common stock for each Abbott common
share held as of the Record Date.
AbbVie was incorporated in Delaware on April 10, 2012 to hold Abbott's
former research-based pharmaceuticals business. AbbVie's common stock began
trading "regular-way" under the ticker symbol "ABBV" on the New York Stock
Exchange on January 2, 2013.
AbbVie is a global, research-based biopharmaceutical company. AbbVie
develops and markets advanced therapies that address some of the world's most
complex and serious diseases.